Company: SUPN
Filing Date: 2025-06-16
Form Type: 8-K
Source: 0001104659-25-059687
Chunk: 1

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: 8-K
Item: Item 1.01
Chunk 1
---
 rights agreement (the “ CVR Agreement”) to
allow for the payment of the Milestones Payment(s) pursuant to each CVR. Through a collaboration agreement with Biogen, Inc.
(“ Biogen”), the Company will report collaboration revenue that is 50% of total net revenue Biogen records for Zurzuvae in the United States. The Milestone Payment(s) that may be paid pursuant to each CVR are: (i) $1.00 payable if in
any calendar year by the end of 2027, annual net sales of Zurzuvae allocable to Supernus equal at least $250 million in the United
States (the “ U. S.”), (ii) $1.00 payable if in any calendar year by the end of 2028, annual net sales of Zurzuvae
allocable to Supernus equal at least $300 million in the U. S., (iii) $1.00 payable if in any calendar year by the end of 2030,
annual net sales of Zurzuvae allocable to Supernus reach $375 million in the U. S., and (iv) $0.50 payable upon the first commercial
sale in Japan to a third-party customer after regulatory approval for Zurzuvae in Japan by Shionogi & Co.,
Ltd., Sage's collaboration partner in Japan, for the treatment of Major Depressive Disorder by June 30, 2026. Each milestone with
respect to a CVR may only be achieved one time and each Milestone Payment will only be paid once in connection with the achievement
of the related milestone. The maximum amount payable with respect to the CVRs issued in respect to each Share is $3.50.

When commenced, the Offer will
initially remain open for 20 business days following commencement of the Offer. If, at the scheduled expiration time of the Offer, any
of the conditions to the Offer have not been satisfied (unless such condition is waivable by the Company or Purchaser and has been waived),
Purchaser may extend the Offer for subsequent periods of up to 10 business days each. Additionally, Purchaser must extend the Offer (i)
for any period required by applicable law (including any applicable interpretations or positions of the U. S. Securities and Exchange Commission
(the “ SEC”), the SEC staff and the Nasdaq Global Market), (ii) for periods of up to 10 business days each until the expiration
or termination of the waiting period (